Ondine Biomedical, Inc. ( (GB:OBI) ) just unveiled an announcement.
Ondine Biomedical Inc. announced that University Hospital Zurich has started an independent clinical study on its Steriwave nasal decolonization technology, marking its first use in Switzerland. The study aims to evaluate Steriwave’s effectiveness in reducing preoperative nasal microbial burden, a key factor in surgical site infections. This deployment is part of Ondine’s mission to provide innovative solutions for infection prevention and address antimicrobial resistance, building on its established use in Canada and the UK.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection. The company has developed a range of investigational products based on its proprietary technology, including the Steriwave nasal photodisinfection system, which is approved in several countries and is undergoing clinical trials in the US. Ondine’s products target various medical conditions such as chronic sinusitis and ventilator-associated pneumonia.
Average Trading Volume: 267,855
Technical Sentiment Signal: Buy
Current Market Cap: £41M
Learn more about OBI stock on TipRanks’ Stock Analysis page.